Protagonist to Present Preclinical Findings on PTG-200 for Crohn’s Disease at Conference

Protagonist to Present Preclinical Findings on PTG-200 for Crohn’s Disease at Conference
Protagonist Therapeutics will present preclinical research data on its investigational drug PTG-200 as a potential treatment for Crohn’s disease. The findings will be presented May 6 at the Digestive Disease Week conference taking place May 6-9 in Chicago, the company announced in a press release. In the presentation titled “The Biomarker Profile of PTG-200, an Oral Peptide

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *